SCHEMBL718970

SCHEMBL718970

COc1cc2oc(-c3ccccc3)cc(=O)c2c(O)c1O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 6/20 0.81
ABCG2 Q9UNQ0 4/20 0.81
PRSS1 P07477 2/20 0.70
PRSS2 P07478 2/20 0.70
CREB1 P16220 2/20 0.70
PRSS3 P35030 2/20 0.70
FLT3 P36888 2/20 0.70
SLCO2B1 O94956 1/20 0.70
KDM4E B2RXH2 8/20 0.68
MAPT P10636 6/20 0.68
ALDH1A1 P00352 5/20 0.68
CYP3A4 P08684 4/20 0.68
HSD17B10 Q99714 4/20 0.68
CYP2C19 P33261 4/20 0.68
TP53 P04637 3/20 0.68
HPGD P15428 3/20 0.68
CYP2C9 P11712 3/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
PTPRS Q13332 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15674607 1.00 ABCB1 (0.81) ABCB1ABCG2PRSS1PRSS2CREB1
SCHEMBL30152130 1.00 ABCB1 (0.81) ABCB1ABCG2PRSS1PRSS2CREB1
SCHEMBL30606765 0.91 KDM4E (0.81) ABCB1ABCG2PRSS1PRSS2CREB1
SCHEMBL28660389 0.91 KDM4E (0.81) ABCB1ABCG2PRSS1PRSS2CREB1
SCHEMBL22068804 0.90 ABCB1 (1.00) ABCB1ABCG2PRSS1PRSS2CREB1
Mosloflavone SCHEMBL971985 0.90 KDM4E (0.81) ABCB1ABCG2PRSS1PRSS2CREB1
Mosloflavone SCHEMBL29477310 0.90 KDM4E (0.81) ABCB1ABCG2PRSS1PRSS2CREB1
SCHEMBL739122 0.89 POLB (0.83) ABCB1ABCG2FLT3SLCO2B1KDM4E
Ladanein SCHEMBL737069 0.88 FLT3 (0.81) ABCB1ABCG2FLT3KDM4EMAPT
SCHEMBL21715982 0.88 ABCB1 (0.74) ABCB1ABCG2PRSS1PRSS2CREB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698662-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2026-02-25 EP claimed
WO-2024220449-A9 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2025-04-03 WO claimed
US-20250011393-A1 FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL NORTH CAROLINA STATE UNIVERSITY 2025-01-09 US claimed
WO-2024220449-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2024-10-24 WO claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
CN-114272169-A Lavender composition, preparation method and application thereof 江苏省中国科学院植物研究所 2022-04-05 CN claimed
CN-113425635-A Elsholtzia extract, its preparation and use 江苏省中国科学院植物研究所 2021-09-24 CN claimed
US-8669048-B2 Pluripotent cell lines and methods of use thereof PARKINSON'S INSTITUTE (US) 2014-03-11 US claimed
US-20120052053-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION THE PARKINSON'S INSTITUTE 2012-03-01 US claimed
CN-102245180-A Compositions and methods for the treatment of altered alpha-synuclein function PARKINSON S INST 2011-11-16 CN claimed
EP-2361089-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION Parkinson's Institute (US) 2011-08-31 EP claimed
US-20100167286-A1 Pluripotent cell lines and methods of use thereof PARKINSON'S INSTITUTE (US) 2010-07-01 US claimed
WO-2010056413-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION PARKINSON'S INSTITUTE (US) 2010-05-20 WO claimed
WO-2010008486-A2 PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF PARKINSONS INSTITUTE (US) 2010-01-21 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
WO-2005020881-A2 COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES SHANGHAI COMMAN PHARMACEUTICAL CO. (US) 2005-03-10 WO claimed
US-20050049206-A1 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) 2005-03-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052053-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION SNCA, PARK7, NLN ABCB1 3788/4885ABCG2 4167/4885PRSS1 2957/4885
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB ABCB1 719/4885ABCG2 23/4885PRSS1 2174/4885
US-20050049206-A1 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases FNTA, COLGALT1, F3 ABCB1 522/4885ABCG2 336/4885PRSS1 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.